279 related articles for article (PubMed ID: 32981299)
1. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
[TBL] [Abstract][Full Text] [Related]
2. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Lobectomy vs Total Thyroidectomy for Intermediate-Risk Papillary Thyroid Carcinoma With Lymph Node Metastasis.
Xu S; Huang H; Huang Y; Qian J; Wang X; Xu Z; Liu S; Liu J
JAMA Surg; 2023 Jan; 158(1):73-79. PubMed ID: 36449303
[TBL] [Abstract][Full Text] [Related]
4. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.
Lee CH; Jung JH; Son SH; Hong CM; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
PLoS One; 2018; 13(8):e0202644. PubMed ID: 30118516
[TBL] [Abstract][Full Text] [Related]
6. Predictors of recurrence after total thyroidectomy plus neck dissection and radioactive iodine ablation for high-risk papillary thyroid carcinoma.
Kim Y; Roh JL; Song D; Cho KJ; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2020 Oct; 122(5):906-913. PubMed ID: 32588461
[TBL] [Abstract][Full Text] [Related]
7. High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer.
Gray KD; Bannani S; Caillard C; Amanat S; Ullmann TM; Romanov P; Brunaud L; Beninato T; Fahey TJ; Mirallie E; Zarnegar R
Surgery; 2019 Jan; 165(1):37-43. PubMed ID: 30274732
[TBL] [Abstract][Full Text] [Related]
8. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
9. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
10. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
11. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
12. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries.
Joung JY; Choi JH; Cho YY; Kim NK; Sohn SY; Kim SW; Chung JH
Am J Clin Oncol; 2016 Aug; 39(4):374-8. PubMed ID: 24732812
[TBL] [Abstract][Full Text] [Related]
14. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial.
Schlumberger M; Leboulleux S; Catargi B; Deandreis D; Zerdoud S; Bardet S; Rusu D; Godbert Y; Buffet C; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Toubert ME; Kelly A; Benhamou E; Borget I
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):618-626. PubMed ID: 29807824
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Radioactive Iodine Ablation Is Sufficient in Patients With Small Papillary Thyroid Cancer Having Minor Extrathyroidal Extension and Central Lymph Node Metastasis (T3 N1a).
Seo M; Kim YS; Lee JC; Han MW; Kim ES; Kim KB; Park SH
Clin Nucl Med; 2017 Nov; 42(11):842-846. PubMed ID: 28832376
[TBL] [Abstract][Full Text] [Related]
16. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
[TBL] [Abstract][Full Text] [Related]
17. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
[TBL] [Abstract][Full Text] [Related]
18. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA
Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
[TBL] [Abstract][Full Text] [Related]
20. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]